Vés al contingut

Joaquin Seras Franzoso

I am researcher and PI at the Drug Delivery & Targeting Group belonging to the "Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation - AVANT " eCORE at Vall d'Hebron Institute of Research (VHIR). I combine this main activity with acting as associate lecturer at the Autonomous University of Barcelona (UAB).

Institucions de les que formen part

Investigador/a principal
Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia
Vall Hebron Institut de Recerca

Joaquin Seras Franzoso

Institucions de les que formen part

Investigador/a principal
Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia
Vall Hebron Institut de Recerca

I am researcher and PI at the Drug Delivery & Targeting Group belonging to the "Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation - AVANT " eCORE at Vall d'Hebron Institute of Research (VHIR). I combine this main activity with acting as associate lecturer at the Autonomous University of Barcelona (UAB).

I performed my PhD at the Autonomous University of Barcelona (UAB, 2012). There, I focused on the development of first-in-class biomedical uses for bacterial Inclusion Bodies (IBs). IBs are recombinant protein deposits, between the nano- and micro scale, historically discarded as waste by products of protein production. My research studied the IB-exerted stimuli on mammalian cell interfaces when producing complex nanotopographies for tissue engineering. After my PhD I devoted myself to expand the catalogue of biomedical uses for IBs, as high added value biomaterials. I engineered IBs to be used as depots for the slow release of therapeutic proteins, polyvalent coatings and immunomodulatory particles.
I moved to Vall d'Hebron Research Institute (VHIR) in 2015 awarded with an AECC post-doctoral fellowship. Here, I have continued my work in the nano-sphere. Particularly, I have participated in the development of Polymeric Micelles (PM) for the PM-mediated intracellular delivery of therapeutic antibodies, targeting cancer stem cell intrinsic drug resistance. In parallel, I started to explore the potential of extracellular vesicles (EVs). First, as central mediators of intercellular communication with roles in cancer cell plasticity regulation and premetastatic niche conditioning. Secondly, exploiting EVs capacity as protein delivery systems. In this regard, I focused on the generation of protein therapeutics loaded in vivo into EVs. This approach combines protein production and NP functionalization in a single step with intended applications in rare diseases and cancer therapy.

I have participated in >20 competitive projects with an accumulated funding of > 3 Milion euros (PI of two). This activity rendered >50 articles (hi=25) in international journals and >60 contributions to congresses. Complementing this activity I engaged teaching undergraduates (2010-2012 & 2021 - , AQU Lecturer accreditation) at UAB and mentoring master and PhD students.

Línies de recerca

Estudi de les bases moleculars i cel·lulars del càncer

IP: Joaquin Seras Franzoso

Projectes

EXPAND-EV: EXPANDing the value of Extracellular Vesicles as carriers of biomarker and therapy in precision healhcare

IP: Joaquin Seras Franzoso
Col·laboradors: -
Entitat finançadora: EUROPEAN COMMISSION
Finançament: 82800
Referència: EXPAND-EV/EC/MSCA-SE/2024/SERAS
Durada: 01/01/2025 - 31/12/2028

Impact of stem-related tumor extracellular vesicles subsets in TNBC progression.

IP: Joaquin Seras Franzoso
Col·laboradors: Maria Fidel Lledò, Miriam Izquierdo Sans
Entitat finançadora: Instituto de Salud Carlos III
Finançament: 119567
Referència: FI23/00223
Durada: 15/01/2024 - 14/01/2028

MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small Cell Lung Cancer

IP: Ibane Abasolo Olaortua
Col·laboradors: Joaquin Seras Franzoso, Fernanda Raquel Da Silva Andrade, Fernanda Raquel Da Silva Andrade, Fernanda Raquel Da Silva Andrade, Fernanda Raquel Da Silva Andrade
Entitat finançadora: Ministerio de Ciencia e Innovación-MICINN
Finançament: 333099
Referència: CPP2022-009780
Durada: 01/07/2023 - 30/06/2026

Ministerio de Ciencia

Nanoclustered Affimers for Targeted KRAS Ablation in Pancreatic Ductal Adenocarcinoma

IP: Joaquin Seras Franzoso
Col·laboradors: Diana Fernandes de Rafael
Entitat finançadora: Asociación Cáncer de Páncreas
Finançament: 50000
Referència: ACANPAN/PROJECTES/2023/SERAS
Durada: 05/12/2023 - 04/12/2025

Notícies relacionades

La Dra. Diana Fernandes de Rafael i Arthur Cardoso han estat seleccionats per les beques de postdoctorat Junior Leader i de doctorat INPhINIT, respectivament.

El 15 de març s’ha celebrat una Jornada de Portes Obertes on la ciutadania ha pogut conèixer les noves instal·lacions i alguns dels projectes dels nostres grups.

Una jornada organitzada en el marc del Dia Mundial contra el Càncer posa el focus en les últimes innovacions en el camp.

Professionals relacionats

Ruth Blanco Colino

Ruth Blanco Colino

Investigador/a predoctoral
Cirurgia general
Llegir més
Victor José Gallardo Lopez

Victor José Gallardo Lopez

Tècnic de recerca
Cefalea i dolor neurològic
Llegir més
Susana Anfosso Llopis

Susana Anfosso Llopis

Malalties infeccioses
Llegir més
Berta Miró Cau

Berta Miró Cau

Tècnic/a Superior Recerca
Unitat d'Estadística i Bioinformàtica (UEB)
Direcció de Transformació Digital
Llegir més

Subscriu-te als nostres butlletins i forma part de la vida del Campus

El Vall d’Hebron Barcelona Hospital Campus és un parc sanitari de referència mundial on assistència, recerca, docència i innovació es donen la mà.